
We’re proud to share that CHU de Liège, a leading academic hospital in Belgium, is advancing precision oncology with SOPHiA GENETICS. The public hospital is addressing complex cancers, including solid tumor cancers and blood cancers such as chronic lymphocytic leukemia (CLL) and myeloid malignancies, using the advanced analytics and AI-powered SOPHiA DDM™ Platform.
By leveraging SOPHiA DDM™ across solid tumor and hematologic applications, CHU de Liège is streamlining the analysis of complex genomic data to obtain critical insights quickly.
We’re honored to continue working alongside CHU de Liège as part of our global community of healthcare institutions dedicated to advancing precision medicine.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.